Lisinopril/Hydrochlorothiazide
Brand names: Zestoretic, Lisinopril-Hydrochlorothiazide
At a glance
- Medicare prescriptions, 2024
- 4,984,510
- Medicare drug cost
- $41.7M
- Average cost per prescription
- $8.36
- Clinicians who prescribed it
- 132,971
Where it is prescribed
List the prescribers in any state, county, city or ZIP code →
What it is used for
Lisinopril and Hydrochlorothiazide Tablets, USP are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including lisinopril and hydrochlorothiazide. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits.
From the FDA-approved prescribing information (label dated July 2026). Full labels on DailyMed (opens in a new tab)
Boxed warning
WARNING: FETAL TOXICITY When pregnancy is detected, discontinue Lisinopril and Hydrochlorothiazide Tablets as soon as possible. Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus. See WARNINGS, Fetal Toxicity.
The FDA’s strongest warning on a label. It doesn’t mean the drug is unsafe for most people; talk to your doctor or pharmacist before stopping or changing any medicine.
Who prescribes it
- Family Medicine 44.4%
- Internal Medicine 25.4%
- Nurse Practitioners 16.8%
- Physician Assistants 6.1%
- Cardiology 2.4%
- General Practice 1.3%
- Interventional Cardiology 0.9%
- Geriatric Medicine 0.6%
- Endocrinology & Diabetes 0.3%
- Nephrology (Kidney) 0.2%
- Hospitalist 0.2%
- Pediatrics 0.2%
All prescribers, by place, name or specialty →
Share of Medicare prescriptions written by each specialty. Select one to list its prescribers.
Trend, 2019–2024
Medicare prescriptions fell 14% from 2019 to 2024.
Biggest change by state since 2019
- Washington −2%
- New Hampshire −2%
- Utah −2%
- North Dakota −3%
- Hawaii −4%
- Mississippi (smallest change) −30%
- South Carolina (smallest change) −26%
From CMS’s yearly state and national Part D summaries, which count every prescriber, including those CMS leaves out of its per-clinician data (fewer than 11 prescriptions). That is why these totals are higher than the count at the top of this page. Prescriptions include refills.
What it looks like
Pills from 1 maker on file. The same medicine can look different depending on who made it, so check the imprint (the letters and numbers on the pill) with your pharmacist if a refill looks different.
Aurobindo Pharma Limited
| Strength | Looks like | Imprint |
|---|---|---|
| 10 mg / 12.5 mg hydrochlorothiazide | pink round tablet, 7 mm | A 26 |
| 20 mg / 12.5 mg hydrochlorothiazide | yellow round tablet, 8 mm | A 28 |
| 20 mg / 25 mg hydrochlorothiazide | pink round tablet, 8 mm | A 27 |
Source: DailyMed (U.S. National Library of Medicine), from each maker’s FDA drug listing. A few makers are shown, not every one. Never take a pill you can’t identify; ask a pharmacist.
Industry payments about this drug
No industry payments to clinicians named this drug in 2025.
Recalls and shortages
Not on the FDA drug shortage list.
2 recalls since 2020
- Jun 2025 · Lupin Pharmaceuticals Inc. · Class II
Product Mix Up: This product is being recalled because of a complaint received that a sealed bottle of lisinopril and hydrochlorothiazide tablets 20mg/12.5 mg had a foreign tablet identified as atazanavir and ritonavir tablet 300mg/100mg. - Jan 2022 · Cardinal Healthcare · Class II
CGMP Deviations: Products were exposed to temperatures outside of the products labeled storage conditions.
Recalls usually affect specific lots from one maker, not every version of a drug. Class I is the most serious; most drug recalls are Class II. FDA recalls (opens in a new tab)
Sources: CMS Medicare Part D Prescribers by Provider and Drug (2024; prescriptions include refills, and CMS hides counts under 11 per prescriber); U.S. Food and Drug Administration, openFDA (drug labels, NDC directory, enforcement reports, drug shortages); CMS Open Payments 2025; ClinicalTrials.gov. General information only, not medical advice; not yet reviewed by our medical reviewer.